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Abstract
This paper covers several pathogenic theories of Parkinson’s disease (PD); the physiology and biological pathways involved. This
includes a mitochondrial DNA (mtDNA) route, a nuclear DNA route, and other hypotheses about idiopathic PD. The subsequent
discussion of PD symptoms utilizes a neurological perspective, analyzing the neuroanatomical systems involved, and how they
are treated. This includes medications and surgical techniques that are employed in an effort to manage symptomatology and
increase health-related quality of life.
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Introduction
Neurodegenerative diseases are characterized by progressive and selective loss of anatomically or physiologically related neuron systems. The clinical syndromes associated with particular neuroanatomical patterns of cell
loss and dysfunction are typically categorized by whether
they initially affect cognition, movement coordination,
sensation, vision, or autonomic control. Typical examples
of such neurodegenerative diseases include Alzheimer’s
disease, Huntington’s and Parkinson’s disease (Lezi and
Swedlow, 2012). Cholinergic neurons are implicated in
Alzheimer’s, and a degeneration of neurons in the dopaminergic system is responsible for Parkinson’s disease.
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, afflicting 1-3% of the 65+ age
group. It is characterized by accumulation of abnormal
protein (Lewy bodies) in the dopaminergic neurons of
the substantia nigra pars compacta (SNc) and their
subsequent degeneration. These are abnormal circular
structures with a dense protein core and a halo of radiating fibers. They consist of aggregations of misfolded
α-synuclein along with neurofilaments and other proteins. This neuron loss leads to a difficulty controlling
movement. The motor symptoms include bradykinesia,
postural instability, muscle rigidity, and tremors. Some
of the non-motor symptoms (NMS) include depression,
insomnia, anxiety, apathy, psychosis, incomplete bowel
emptying, impulse control disorders, and dementia.
The disease involves progressive degeneration which,
as of now, cannot be stopped or slowed. There are effective medications that can be used to compensate for dopaminergic neuron loss, such as L-dopa, and other types
of dopamine (DA) agonists. These work by increasing the
potency of the surviving neurons and synapses, but only
temporarily. Eventually, the disease will wipe out these
pathways entirely. Furthermore, the disease spreads to
other regions of the brain and causes other symptoms.
For example, when neurodegeneration spreads to cholinergic neuronal pathways, the patient will start to show
signs of dementia. For now, treatment options are limited

to symptom management. This paper discusses some of
those treatment options, but first it is important to consider the PD pathogenesis and symptom origin. Then, this
paper will delve into the innovations available for those
suffering from PD, and explain how they work.
Mitochondrial Pathogenesis of PD
Mitochondria are the site of bioenergetics and biosynthesis in the cell. Hans Krebs, for whom the tricarboxylic
acid (TCA) cycle is named, said of his discovery “in some
micro-organisms the cycle primarily supplies intermediates rather than energy, whilst in the animal and most
other organisms it supplies both energy and intermediates”. The energy supplied by the TCA cycle is in the
form of NADH and FADH2, whose electrons are then
fed into the electron transport chain (ETC) to pump protons into the inner membrane space of the mitochondrion creating a pH gradient. This gradient is then used to
power the conversion of ADP into ATP. A high ATP/ADP
ratio is required to catalyze the chemical reactions that
comprise many of the metabolic operations of the cell.
Additionally, many of the building blocks that a cell
needs to form its assortment of macromolecules are
made using the intermediates of glycolysis and the citric acid cycle. For example, about half of the 20 amino
acids found in human protein can be synthesized in vivo
through the modification of Krebs Cycle intermediates
(Reece et al., 2011). Also fatty acids are synthesized from
acetyl CoA, which is produced by the conversion of pyruvate within the mitochondria. It is important to note
that when the mitochondria are employed in an anabolic
capacity (the building of larger molecules and utilization
of TCA intermediates) they are no longer producing ATP
but consuming this molecule.
There is some evidence implicating mutations in mitochondrial DNA (mtDNA) or nuclear genes coding for
mitochondrial protein in the pathogenesis of PD. Several
research teams working in 1989 reported a reduction of
activity of Complex 1 of the ETC in the substantia nigra
in patients with idiopathic PD (Lezi and Swedlow, 2012).
This study was based on reports of healthy individuals developing Parkinson’s like symptoms after consuming the
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP). It was determined that the active metabolite
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of MPTP is taken up by the cell via the dopamine transporters, allowing them to cluster and wreak havoc in dopaminergic neurons. This particular metabolite inhibits
Complex 1 of the electron transport chain, which was
assumed to have led to the exhibition of Parkinson’s
symptomatology.
The suggested hypothesis is that mutations within
genes coding for mitochondrial DNA or in mtDNA itself, specifically Complex 1 genes, can be implicated in PD
pathogenesis. Complex 1 contains 46 protein subunits,
seven of which are encoded by mtDNA. A mutation
causing a decrease in Complex 1 activity would lead to
a drop in ATP production and increased oxidative stress
and cellular deterioration from the accumulation of free
radicals (Lezi and Swedlow, 2012).
It is unclear why dopaminergic neurons of the substantia nigra would be uniquely susceptible. However, what
is clear is that the failure of these nigral dopaminergic
systems are responsible for the symptoms of PD. Based
on the research done on mitochondrial involvement in
dopaminergic deterioration in PD or induced PD symptoms, there is sufficient justification to investigate treatment options targeting the mitochondria, which work to
encourage proper functionality and cellular respiration
(Lezi and Swedlow, 2012).
α-synuclein and PD
Researchers have discovered that a mutation on chromosome 4 will produce PD (Polymeropoulos, et al., 1996),
the gene that codes for α-synuclein. This protein can be
found in the axon terminals and is involved in synaptic
transmission in dopaminergic neurons. A mutation in this
gene can result in a mistranslated and subsequently misfolded α-synuclein that is toxic to the cell. These proteins
group together in large aggregates called Lewy bodies
which devastate normal cell function.
The majority of PD cases are sporadic. They occur
without any family history or hereditary basis for the disorder. Some researchers suggest that an unknown toxin
in the environment, faulty metabolism, or infection may
be the culprit in these cases. There are two insecticides
that are known to cause PD, and presumably there may
be more. These toxins might interfere with mitochondrial signaling which, when impaired, could cause these
aggregations of α-synuclein to resist degradation and persist in the cytoplasm of nigral neuron systems.
Symptoms and Their Physiology
The loss of the brain’s most important dopamine suppliers, the neurons of the SNc, leads to a variety of
symptoms. Resultant motor symptoms include tremors,
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muscle rigidity, bradykinesia, and postural imbalance the symptoms that normally come to mind when people think of Parkinson’s disease. These symptoms arise
directly from neuron loss in the motor regulation centers of the brain (Carlson & Birkett, 2017). Additionally,
many other neural pathways are affected by damage to
the substantia nigra, such as the areas where these dopaminergic neurons project, namely, the basal ganglia and
the nucleus accumbens. The basal ganglia are involved in
controlling movement, but they also project to the frontal
lobes of the brain and play a role in thinking and executive functions. The nucleus accumbens has been linked
to behavioral regulation, Thus, dopamine irregularities in
this region can lead to changes in personality (Carlson &
Birkett, 2017).
The causes for some of the non-motor symptoms are
pretty clear, while others are more complicated and debatable. Some symptoms arise directly from a decrease in
dopamine (DA) production in the substantia nigra. Other
symptoms are a result of the DA agonist prescribed to
the patient. This might be due to the dramatic fluctuations of DA in the brain owing to the medication schedule. Still other symptoms might be due to an increased
potency in certain dopaminergic systems that have not
been impacted by the disease. When the patient takes
L-dopa, these functioning dopaminergic neurons release
too much DA. This DA flood triggers a deficit in executive functions, according to the Dopamine Overdose
Hypothesis (Dirnberger & Jahanshahi, 2013).
Other symptoms result from unrelated pathways that
happen to be proximal to damaged areas of the brain.
Lewy bodies are often present in the dopaminergic neurons of those with PD. Many of these misfolded proteins
that cause neurodegeneration can be transferred from
cell to cell (Lee, et al., 2011). This perhaps explains how
the serotonergic, noradrenergic, and cholinergic systems
become impacted in later stages of PD.
Treatments
Since there is no cure for PD, the standard treatment is
symptom management, by way of DA agonists. The most
common one in use is L-dopa, a neurotransmitter (NT)
precursor which dopaminergic neurons can convert to
dopamine. This maximizes its potency through increasing the amount of NT present in the synaptic cleft with
each firing of the surviving neurons. When other systems
are involved in degeneration, such as the serotonergic,
noradrenergic, and cholinergic systems, agonists for each
of those NTs can be used to alleviate symptoms. Some
symptoms arise from too much dopamine in the healthier
dopamine pathways, or fluctuations of dopamine based
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on medication schedule (Dirnberger & Jahanshahi, 2013).
These symptoms can be treated by using different DA
agonists at different times and by changing doses. The
reason for the variety of dopamine agonists is to reduce
fluctuations and mitigate some symptoms that may arise
from any one particular DA agonist.
Another possible medication is Deprenyl, which was
initially discovered to be effective after the outbreak of
PD among users of the drug MPTP. The idea behind it
was to inhibit the activity of the monoamine oxidase-B
enzyme and hopefully block the toxins from attacking and
damaging the neurons. Although the drug does alleviate
symptoms, it does not reverse, stop, or slow the progression of disease (Williams, 2010).
One surgical technique involved the grafting of nigral
neurons taken from aborted fetuses, to replace the ones
lost to PD. This was shown to work particularly well in
patients who responded well to L-dopa earlier in the disease. Presumably, these patients had enough healthy neurons in the basal ganglia to process and secrete dopamine,
whether intrinsic or from grafted tissue. Unfortunately,
many of these patients later developed debilitating dyskinesias and the surgery is no longer recommended
(Olanow, et al., 2003).
Upon closer inspection, it seemed as though the fetal
tissue had been successful in making the proper connections with the basal ganglia. However, with time, the
aggregate α-synuclein deposits made their way from damaged host cells to transplanted healthy cells (Kordower, et
al., 2011). Any misfolded proteins responsible for neurodegeneration can be transferred from cell to a cell close
by (Lee, et al., 2011). It seems that adding healthy cells to
the basal ganglia will not work unless a way is found to
prevent the α-synuclein from aggregating in the first place
and spreading to neighboring cells.

to L-dopa. Neurosurgeons can get similar results by
destroying the subthalamic nucleus (STN) (Guridi, J &
Obeso, 2001), which has an excitatory effect on GPi.
Another option that is growing in popularity due to refined surgical techniques is deep brain stimulation (DBS).
Here, instead of destroying GPi and STN, microelectrodes
are placed in these regions for the patient to stimulate as
needed. This technique is as effective as brain lesions in
suppressing tremors but with fewer risks (Esselink, et al.,
2009). DBS might also be effective against depression and
cognitive impairment in PD.

GPi and STN Related Therapies
The main output of the basal ganglia is from the internal
division of the globus pallidus (GPi) and it is inhibitory.
Researchers found that whenever there is a decrease of
activity to the putamen and the caudate nucleus (which
is a byproduct of SNc neuron death due to PD) there is
an increase in inhibitory signaling from GPi to the motor
cortex. It was suggested that destroying this area might
help mitigate some of the motor symptoms. This strategy worked well and was a pretty good option but the
surgery was quite risky. The optic tract is located quite
proximal to the GPi and some patients were blinded by
the surgery. Due to advancements in imaging and surgical
techniques, this option has become safer, and can be recommended for younger patients who no longer respond
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Conclusion
There are some innovative techniques for treating PD
and a lot of promising research on the horizon. Through
pursuit of the various pathogenesis hypotheses, we are
getting closer to understanding the mechanisms of neurodegeneration. This information is crucial to finding a
strategy to reverse the disease progression. In the meantime, there are many interventions available to those
suffering from PD that can dramatically improve quality
of life. It is a devastating diagnosis to receive but there
is plenty of hope. It is crucial that those diagnosed with
PD are taught about the potential symptoms and how
they can be treated. Specifically the many non-motor
symptoms not directly caused by degeneration of dopaminergic neurons. Treatment of these symptoms is
achieved through some of the more creative and innovative treatments discussed in this paper. These non-motor symptoms are less known by the patients but were
found to be more injurious to the patient’s quality of life
than the classic symptoms (Duncan, et al., 2013). As the
research into PD genesis, pathways and mechanisms develops, more therapies are being discovered to treat this
complex and multifaceted disease.
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